Summary Comments
- Most frequently detected viruses during February 2024 (all age groups):
- Rhino/Enterovirus: 36.6%
- Rhinovirus: 32.6%
- Parainfluenza virus 1–4: 9.8%
- Epidemiological Week 1–9:
- SARS-CoV-2: Stable positivity over the last 5 weeks.
- Influenza A: 2.6% positivity in week 9.
- Influenza B: 3.7% positivity in week 9.
- RSV: Increasing trend, reaching 12.8% in week 9.
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
January 2024:
- Rhino/Enterovirus: 24.3%
- Rhinovirus: 21.2%
- SARS-CoV-2: 8.78%
- RSV: 2.2%
- Parainfluenza 1-4: 3.0%
- Adenovirus: 6.9%
- Influenza A: 3.0%
- Influenza B: 3.1%
February 2024:
- Rhino/Enterovirus: 36.6%
- Rhinovirus: 32.6%
- SARS-CoV-2: 5.3%
- RSV: 7.9%
- Parainfluenza 1-4: 9.8%
- Adenovirus: 7.7%
- Influenza A: 3.7%
- Influenza B: 1.0%
Weekly Positivity Trends (Week 1–9):
- SARS-CoV-2: Stable
- Influenza A: 2.6% (week 9)
- Influenza B: 3.7% (week 9)
- RSV: Increased to 12.8% (week 9)
Atypical Bacterial Pathogens (Week 1–9)
Weekly Case Totals:
- Bordetella pertussis: 5, 9, 7, 6, 9, 9, 5, 6, 4
- Mycoplasma pneumoniae: 5, 15, 13, 23, 10, 11, 15, 20, 14
- Chlamydia pneumoniae: 5, 7, 10, 8, 18, 12, 15, 22, 7
Legionella pneumophila:
- 4 cases detected during February 2024
Age Distribution (Week 1–9):
B. pertussis:
- 0–6 months: 17%
- 6–12 months: 10%
- 1–5 years: 28%
- 6–12 years: 15%
- 13–18 years: 2%
- 19–64 years: 29%
65 years: 0%
M. pneumoniae:
- 0–6 months: 2%
- 6–12 months: 7%
- 1–5 years: 27%
- 6–12 years: 29%
- 13–18 years: 6%
- 19–64 years: 22%
65 years: 7%
C. pneumoniae:
- 0–6 months: 1%
- 6–12 months: 2%
- 1–5 years: 51%
- 6–12 years: 30%
- 13–18 years: 3%
- 19–64 years: 13%
65 years: 0%
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
January 2024:
- Rhino/Enterovirus: 35.1%
- Rhinovirus: 27.4%
- RSV: 5.8%
- Parainfluenza 1-4: 8.8%
- Adenovirus: 8.7%
- SARS-CoV-2: 1.2%
- Influenza A: 5.3%
- Influenza B: 1.8%
February 2024:
- Rhino/Enterovirus: 42.2%
- Rhinovirus: 34.3%
- RSV: 18.3%
- Parainfluenza 1-4: 11.9%
- Adenovirus: 6.6%
- SARS-CoV-2: 1.2%
- Influenza A: 5.7%
- Influenza B: 1.3%
1–5 Year Age Group
January 2024:
- Rhino/Enterovirus: 44.3%
- Rhinovirus: 37.5%
- RSV: 4.6%
- Parainfluenza 1-4: 9.7%
- Adenovirus: 13.3%
- SARS-CoV-2: 1.4%
- Influenza A: 4.6%
- Influenza B: 5.8%
February 2024:
- Rhino/Enterovirus: 55.5%
- Rhinovirus: 47.8%
- RSV: 14.4%
- Parainfluenza 1-4: 17.9%
- Adenovirus: 8.0%
- SARS-CoV-2: 1.7%
- Influenza A: 6.7%
- Influenza B: 2.4%
6–12 Year Age Group
January 2024:
- Rhino/Enterovirus: 33.5%
- Rhinovirus: 31.3%
- RSV: 0.6%
- Parainfluenza 1-4: 1.4%
- Adenovirus: 4.2%
- SARS-CoV-2: 0.3%
- Influenza A: 3.6%
- Influenza B: 7.8%
February 2024:
- Rhino/Enterovirus: 43.6%
- Rhinovirus: 40.1%
- RSV: 2.5%
- Parainfluenza 1-4: 5.5%
- Adenovirus: 2.8%
- SARS-CoV-2: 0.6%
- Influenza A: 4.2%
- Influenza B: 7.6%
Continue Reading